Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...

Q3 2025 Management View CEO Shawn Singh outlined the company’s progress on its lead clinical programs, particularly fasedienol, which is being developed for the acute treatment of social anxiety ...

Mental health professionals reveal the hidden signs of anxiety disorders affecting millions of Americans, from mysterious ...

Reports Q3 revenue $234,000, consensus $179.25k. “We had a very productive quarter, with both PALISADE-3 and PALISADE-4 advancing towards ...

The musical centers on Evan Hansen, a lonely high school teenager who suffers from social anxiety. When a letter he writes ...

Social technologies present a unique paradox—they can be connectors and disruptors. They can simultaneously offer lifelines ...

People who experience high levels of social anxiety may show a weaker cardiovascular response to stressful situations, and ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...

Discover why silence feels uncomfortable, how it affects anxiety and relationships, and strategies to embrace quiet moments ...

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 ...

The findings are mixed due to differing scenarios and types of anxiety symptoms. Social Anxiety Disorder While beta-blockers like propanolol are helpful due to their ability to lessen the physical ...

Cynophobia, the irrational fear of dogs, is more common than many realise and can range from mild discomfort to a ...